生命科学资讯

Lilly bets again on China drugs; Roche showcases MS data

#ACTRIMS26: Roche’s MS drug fenebrutinib beats Ocrevus, cutting risk of disability progression by 12%

Roche unveils data behind BTK inhibitor's phase 3 multiple sclerosis win in Ocrevus trial - Fierce Biotech

Roche’s Genentech cut at least 489 jobs last year, new disclosure reveals

Genentech cut at least 489 jobs last year, new filing reveals - Fierce Biotech

Roche's return to RNA continues with $1.7B deal for Sanegene program

Roche continues RNA return with $1.7B deal for Sanegene drug - Fierce Biotech

Roche Expands Clinical Research in Mexico, Invests MX$1.2 Billion - Mexico Business News

Roche’s 2025 profit blunted by weakened US dollar - Medical Device Network

Roche’s 2025 profit blunted by weakened US dollar - Pharmaceutical Technology

Roche diagnostics business nudges up 2% in '25 as China headwinds buffet Asia-Pacific sales

Roche GLP-1 produces “robust” weight loss in late-stage obesity trial - European Pharmaceutical Review

Roche drops $100M Kiniksa fibrosis drug from phase 2 pipeline as part of quarterly clearout - Fierce Biotech

Roche Reports Positive Phase II Study Results for Dual GLP-1/GIP Receptor Agonist | PharmExec - Pharmaceutical Executive

Roche, trailing in obesity, showcases new data for GLP-1 shot

How Roche is Scaling Production After Obesity Breakthrough - Manufacturing Digital Magazine

Roche sees GLP1/GIP drug from Carmot produce 22.5% weight loss, readies phase 3 trial - Fierce Biotech

Roche announces positive phase II results for experimental obesity drug - wkzo.com

Roche's Gazyva gets Health Canada approval for lupus nephritis - marketscreener.com

Roche boosts NC factory investment to $2B; Rentschler CEO steps down